Intra-Cellular Therapies, Inc. Forecasted to Post FY2025 Earnings of $1.50 Per Share (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) – Equities research analysts at Leerink Partnrs raised their FY2025 earnings estimates for shares of Intra-Cellular Therapies in a report issued on Tuesday, May 7th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will post earnings per share of $1.50 for the year, up from their prior estimate of $1.35. The consensus estimate for Intra-Cellular Therapies’ current full-year earnings is ($0.59) per share. Leerink Partnrs also issued estimates for Intra-Cellular Therapies’ FY2026 earnings at $3.15 EPS and FY2028 earnings at $6.80 EPS.

A number of other research analysts have also recently weighed in on ITCI. Mizuho lifted their price objective on shares of Intra-Cellular Therapies from $82.00 to $96.00 and gave the company a “buy” rating in a report on Monday, April 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $120.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday, April 24th. TD Cowen lifted their target price on Intra-Cellular Therapies from $80.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Bank of America upped their price target on Intra-Cellular Therapies from $82.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Finally, Canaccord Genuity Group lifted their price objective on Intra-Cellular Therapies from $100.00 to $107.00 and gave the company a “buy” rating in a research note on Tuesday, April 23rd. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Intra-Cellular Therapies has a consensus rating of “Moderate Buy” and a consensus price target of $90.17.

Intra-Cellular Therapies Price Performance

NASDAQ ITCI opened at $65.56 on Thursday. The company has a market cap of $6.35 billion, a P/E ratio of -44.90 and a beta of 1.01. Intra-Cellular Therapies has a 1-year low of $45.50 and a 1-year high of $84.89. The stock has a 50-day moving average of $68.95 and a two-hundred day moving average of $65.86.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.15. Intra-Cellular Therapies had a negative return on equity of 23.02% and a negative net margin of 30.08%. The business had revenue of $144.90 million during the quarter, compared to analyst estimates of $141.41 million. During the same period last year, the business posted ($0.46) earnings per share. The company’s quarterly revenue was up 52.0% on a year-over-year basis.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ITCI. Vanguard Group Inc. boosted its stake in shares of Intra-Cellular Therapies by 6.5% during the fourth quarter. Vanguard Group Inc. now owns 9,094,302 shares of the biopharmaceutical company’s stock worth $651,334,000 after buying an additional 554,577 shares during the period. Wasatch Advisors LP lifted its position in Intra-Cellular Therapies by 6.3% during the 1st quarter. Wasatch Advisors LP now owns 3,854,747 shares of the biopharmaceutical company’s stock worth $266,748,000 after acquiring an additional 227,439 shares during the period. Avoro Capital Advisors LLC purchased a new position in shares of Intra-Cellular Therapies in the 4th quarter valued at approximately $161,543,000. JPMorgan Chase & Co. increased its holdings in shares of Intra-Cellular Therapies by 4.4% in the third quarter. JPMorgan Chase & Co. now owns 2,063,802 shares of the biopharmaceutical company’s stock valued at $107,503,000 after purchasing an additional 86,388 shares during the period. Finally, Wellington Management Group LLP raised its stake in shares of Intra-Cellular Therapies by 6.7% during the third quarter. Wellington Management Group LLP now owns 1,815,954 shares of the biopharmaceutical company’s stock worth $94,593,000 after purchasing an additional 114,370 shares during the last quarter. 92.33% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Intra-Cellular Therapies

In related news, EVP Suresh K. Durgam sold 6,450 shares of Intra-Cellular Therapies stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $66.56, for a total transaction of $429,312.00. Following the sale, the executive vice president now directly owns 16,170 shares in the company, valued at approximately $1,076,275.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Suresh K. Durgam sold 6,450 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $66.56, for a total transaction of $429,312.00. Following the transaction, the executive vice president now owns 16,170 shares in the company, valued at approximately $1,076,275.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael Halstead sold 7,345 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $65.97, for a total value of $484,549.65. Following the completion of the sale, the executive vice president now owns 19,803 shares of the company’s stock, valued at approximately $1,306,403.91. The disclosure for this sale can be found here. In the last quarter, insiders sold 168,487 shares of company stock worth $11,364,950. 3.40% of the stock is currently owned by insiders.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.